New MammaTyper? research launched at EBCC this week
The Cerca Biotech team is at the 14th European Breast Cancer Conference?this week in Milan Italy. From today (March 20) we will be at booth 8 in the exhibition hall. We have six posters included as part of the programme, spanning research conducted in the UK, Italy, the Netherlands, Belgium and China. If you'd like to meet the people behind the research, chat further about MammaTyper?, or enquire about attending our exclusive event tomorrow evening, come and find us in the hall or drop us a line at [email protected].
The new research covers the role of MammaTyper? at different stages of the breast cancer journey, findings include:?
?Clinical performance and agreement with immunohistochemistry of RT-qPCR-based early breast cancer subtyping
? Correlation between mRNA expression quantified by MammaTyper? and HER2 IHC consensus scores
? Reassessment of HER2 status in invasive micropapillary carcinoma of the breast
? IHC-based and mRNA-based subtyping for triple-negative breast cancer
? Defining and identifying HER2+ patients that would benefit from anti-HER2 therapy
? Prediction of response to neoadjuvant chemotherapy in HER2 positive breast cancer by MammaTyper?
With thanks to the research authors including: Cristian Scatena Emad Rakha Eugenia Belcastro, PhD Antonio Scapinello Vasileios Mourmouras Simona Frezzini Ximena Báez Navarro
#EBCC14 #research #breastcancer #diagnostics